Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluzone® (IM) Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

NCT02242643
View directory record Official record
Conditions
Influenza
Interventions
FluLaval™ Quadrivalent, Fluzone® Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
2,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®

NCT00755274
View directory record Official record
Conditions
Influenza, Orthomyxoviridae Infections
Interventions
Influenza Virus Vaccine No Preservative: Pediatric Dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 5 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

NCT00551031
View directory record Official record
Conditions
Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,098 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
29
States / cities
Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

NCT00662272
View directory record Official record
Conditions
Influenza
Interventions
Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
Biological
Lead sponsor
Colby Pharmaceutical Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

NCT00693706
View directory record Official record
Conditions
Influenza
Interventions
Trivalent influenza vaccine GSK 138842A, Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genetic and Environmental Factors in the Response to Influenza Vaccination

NCT03088904
View directory record Official record
Conditions
Influenza, Healthy
Interventions
FluMist® Quadrivalent, Fluzone® Quadrivalent vaccine
Biological
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 49 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influenza Vaccine Revaccination in Ambulatory Elderly Subjects

NCT00775450
View directory record Official record
Conditions
Influenza, Orthomyxovirus Infection, Myxovirus Infection
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
28
States / cities
Hoover, Alabama • Mobile, Alabama • Chandler, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Modified mRNA Vaccines in Healthy Adults

NCT05397223
View directory record Official record
Conditions
SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
Interventions
mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
8
States / cities
Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

NCT01333462
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
NB-1008, Control
Biological · Other
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

NCT03739112
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
12,794 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
50
States / cities
Mobile, Alabama • Tempe, Arizona • Banning, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults

NCT00623181
View directory record Official record
Conditions
Influenza
Interventions
Fluzone: Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Grove City, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Glendale, Arizona • San Diego, California • Vista, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

NCT02141581
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (IM), Fluzone® Intradermal (ID), 2011-2012 FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 34 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

NCT00388583
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02563093
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

NCT03283319
View directory record Official record
Conditions
Influenza, Human
Interventions
3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7, MF59, AS03
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

NCT02918006
View directory record Official record
Conditions
Influenza
Interventions
VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

NCT05606965
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

NCT02553343
View directory record Official record
Conditions
Influenza
Interventions
High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
792 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 14, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

NCT01974895
View directory record Official record
Conditions
Influenza
Interventions
FluLaval® Quadrivalent, Fluzone®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
12
States / cities
Sacramento, California • West Covina, California • Altamonte Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 14, 2026, 1:56 AM EDT